Skip to main content
BEONE MEDICINES LTD. logo

BEONE MEDICINES LTD. — Investor Relations & Filings

Ticker · 688235 ISIN · CNE100005XT6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 728 across all filing types
Latest filing 2022-05-05 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688235

About BEONE MEDICINES LTD.

https://beonemedicines.com/

BEONE MEDICINES LTD. is a biopharmaceutical company focused on the research, development, and commercialization of innovative therapeutic solutions, primarily in the field of oncology. The company specializes in the discovery of targeted small molecule drugs and biologics designed to address unmet medical needs in cancer treatment. Its research and development pipeline emphasizes precision medicine, utilizing advanced molecular biology and medicinal chemistry platforms to identify novel drug candidates. BEONE MEDICINES LTD. aims to improve patient outcomes by developing high-efficacy, low-toxicity therapies that target specific genetic drivers of disease. The company maintains a strong focus on clinical-stage development and strategic collaborations to advance its portfolio of next-generation medicines.

Recent filings

Filing Released Lang Actions
百济神州有限公司2022年第一季度主要财务数据公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2022年第一季度主要财务数据公告" which translates to "2022 First Quarter Major Financial Data Announcement." It contains detailed financial data for the first quarter of 2022, including revenue, profit, net income, and other financial metrics. The data is preliminary and unaudited, with a note that the official quarterly report will provide the final audited figures. The document includes comprehensive financial figures and explanations of business performance and risks for the quarter ending March 31, 2022. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing substantive financial data and analysis. The document is over 5,000 characters and contains actual financial data, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2022
2022-05-05 Chinese
港股公告：百济神州有限公司截至2022年3月31日止三个月未经审核业绩以及业务进展最新情况
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement from BeiGene, Ltd. regarding its unaudited financial results for the first quarter ending March 31, 2022, including comprehensive financial data such as revenue, expenses, net loss, and per-share information. It also includes extensive business updates, clinical trial progress, milestones, and future outlook. The document references compliance with SEC rules and US GAAP accounting standards, and it contains detailed financial statements (balance sheet and income statement) for the quarter. The length of the document (over 13,000 characters) and the presence of substantive financial data and analysis confirm it is a full financial report rather than a brief announcement or a certification. The document is clearly a quarterly financial report with detailed financial results and business commentary, fitting the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-05-05 Chinese
百济神州有限公司自愿披露关于国家药品监督管理局批准倍利妥（注射用贝林妥欧单抗）用于治疗儿童复发或难治性CD19阳性前体B细胞急性淋巴细胞白血病的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by BeiGene Ltd. regarding the conditional approval by the National Medical Products Administration (NMPA) of a drug product (BLINCYTO) for treating a specific pediatric leukemia. It includes details about the drug, its approval status, potential commercial impact, and risk factors. The document is short (1325 characters) and serves as a regulatory announcement about a product approval and associated risks, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and risk disclosure.
2022-05-04 Chinese
百济神州有限公司关于召开2022年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2022 Annual General Meeting (AGM) of 百济神州有限公司 (BeiGene Ltd.). It includes information about the meeting date, voting methods, agenda items to be voted on, instructions for shareholders, and proxy forms. The content focuses on the logistics and procedural details of the AGM rather than presenting financial results or management analysis. There is no financial data or report content, but rather a formal announcement and materials related to the AGM itself. Therefore, this document fits the category of AGM Information (AGM-R). The document length (7102 characters) and detailed agenda support this classification rather than a brief announcement or a report publication announcement.
2022-05-04 Chinese
港股公告：翌日披露报表
Share Issue/Capital Change Classification · 100% confidence The document is a detailed disclosure report about changes in issued share capital and/or share repurchases by the company 百濟神州有限公司 (BeiGene, Ltd.) as required under the Hong Kong Stock Exchange Listing Rules (Main Board Rule 13.25A and GEM Rule 17.27A). It includes specific data on share issuance dates, share counts, prices, and percentage changes, as well as confirmations that the share issuances were duly authorized and complied with regulatory requirements. The document is structured as a regulatory disclosure form (FF304) specifically for share capital changes and share repurchases. It is not an announcement of a report publication, nor is it a full financial report or management discussion. It is a formal regulatory filing about share capital changes, which fits the definition of Share Issue/Capital Change (SHA). The document length is 3274 characters, which is consistent with a detailed regulatory disclosure rather than a brief announcement or a full annual/interim report.
2022-05-04 Chinese
百济神州有限公司2022年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is a detailed communication to shareholders including a letter from the CEO, financial highlights, strategic updates, and most importantly, a comprehensive notice and circular for the 2022 Annual General Meeting (AGM) of 百济神州有限公司 (BeiGene Ltd.). It includes detailed proposals for shareholder voting such as director elections, auditor appointments, share issuance and repurchase authorizations, equity incentive plans, and advisory votes on executive compensation. The document also provides logistical details about the AGM date, location, voting procedures, and registration dates. The presence of extensive AGM-related materials and the formal notice to shareholders clearly identify this as AGM Information. The document is lengthy (15,000 characters) and contains the actual meeting materials, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the correct classification is AGM Information (AGM-R).
2022-05-04 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.